AGP Executive Report
Last update: 9 hours agoAI in Healthcare: Philips’ 2026 Future Health Index says AI is now embedded in clinical workflows in the U.S., with most clinicians reporting time savings and more focus on patient care. Clinical Trials (Parkinson’s): GEN Pharmaceuticals reports the first patient dosed in its Phase II proof-of-concept trial of SUL-238 for early, untreated Parkinson’s, targeting mitochondrial dysfunction. Rare Disease Access (Spain): Avanzanite expands into Spain and appoints María Baquerizo López-Quectuy as country manager to build local presence for rare-disease therapies. Dutch Drug Access Policy: The Netherlands delays its “Future-Proof Medicines System” (TSG) by six months to January 2028, amid concerns about long patient waiting times. Healthcare Security & Research: Dutch virologist Vincent Munster faces U.S. charges over alleged mpox sample smuggling, drawing attention to cross-border biosecurity and research compliance. Public Health (Hantavirus): Canada reports a recovered hantavirus patient after exposure linked to the Dutch-flagged cruise ship Hondius, with others still in quarantine. Logistics for Medicines: CCT rolls out reusable EcoFlex temperature-controlled pharma shippers across Europe, aiming to cut costs, waste, and emissions. Local Healthcare Tech: Nedap expands its mobile access partnership with Albert Heijn, enabling staff to use smartphones for secure building entry.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
